Patent Exhaustion in Biologics

Introduction

Patent exhaustion refers to the principle that, after an authorised sale of a patented product, the patent holder generally cannot use patent law to control the subsequent use or resale of that particular product. In biologics—medicines produced using living cells or biological systems, such as monoclonal antibodies, vaccines and therapeutic proteins—the doctrine raises complex questions because products may be expensive, require specialised storage and handling, and involve multiple patents covering the molecule, formulation and manufacturing process.

The central challenge is balancing patent holders’ incentives to innovate with patients’ and healthcare providers’ interests in affordable access to biological medicines.

Legal Framework in India

Section 48 of the Patents Act, 1970 grants patentees exclusive rights over patented products and processes, subject to the Act. Section 107A(b) permits the importation of patented products from a person duly authorised under law to produce and sell or distribute them. This provision is relevant to parallel imports, subject to its statutory conditions.

India's approach must also be considered alongside competition law, public-health safeguards and applicable drug-regulatory requirements. Patent exhaustion does not automatically authorise the manufacture of a biosimilar, nor does it replace regulatory approval or applicable quality and safety obligations.

Important Case Laws

1. Impression Products, Inc. v. Lexmark International, Inc., 581 U.S. 360 (2017)

The US Supreme Court held that an authorised sale exhausts patent rights over the particular product sold, even where contractual restrictions purport to limit subsequent use or resale. Such restrictions may potentially be enforceable under contract law, but not through a patent infringement action after exhaustion. Although the case concerned printer cartridges, its principle is relevant to the resale and distribution of biologic medicines.

Justia U.S. Supreme Court Center

+1

2. Bowman v. Monsanto Co., 569 U.S. 278 (2013)

The US Supreme Court held that exhaustion does not permit a purchaser to reproduce patented soybean seeds through planting and harvesting. The doctrine protects the particular item sold, not the creation of new copies. By analogy, the case helps explain why purchasing a biologic does not necessarily authorise manufacturing additional quantities of a patented biological product. The precise application depends on the patent claims and relevant law.

Justia U.S. Supreme Court Center

+1

3. Quanta Computer, Inc. v. LG Electronics, Inc., 553 U.S. 617 (2008)

The US Supreme Court found patent exhaustion where authorised sales of microprocessors substantially embodied the patented inventions. The decision illustrates that exhaustion may apply even where the sold component does not independently practise every element of the patented invention. In biologics, the reasoning may be relevant when a commercially sold component embodies a patented technology, although biological products require a claim-specific assessment.

Significance

Patent exhaustion can support competition and improve access to biologics by allowing legitimate resale and distribution after an authorised sale. However, it does not eliminate patent rights over separately manufactured products or independently patented processes. In India, Section 107A(b) is particularly relevant to authorised parallel imports, while the precise reach of domestic exhaustion must be assessed under applicable Indian law.

The doctrine therefore seeks to prevent repeated patent control over the same sold item without granting purchasers an unrestricted right to manufacture new patented biologics.